Category: Wall Street Beat
Bio-artificial liver maker Vital Therapies takes its IPO even lower, now planning to open at $12 per share.
MASSDEVICE ON CALL — California biotherapeutics company Vital Therapies dropped its per-share price even lower, opening today at $12 per share in the hopes of raising $54 million. Shares are slated to open today on the Nasdaq market under the symbol "VTL."
Cardiac Dimensions raises $20 million from a syndicate of international investors for its Carillon mitral valve implant.
Cardiac Dimensions said it raised $20 million from a syndicate of international investors for its Carillon mitral valve implant.
M.H. Carnegie & Co. and Lumira Capital led the round for Kirkland, Wash.-based Cardiac Dimensions, according to a press release. Investors in Australia, the U.S. and Canada also participated, the company said.
Mainstay Medical looks to raise up to $42 million with an initial public offering on the EuroNext stock exchange.
Mainstay Medical is preparing an initial public offering on the EuroNext stock exchange that could be worth up to $42 million, according to a regulatory filing.
Mainstay, which last month launched a new clinical trial of its ReActiv8 implantable neurostimulator for chronic lower back pain, said it plans to offer some 1.1 million shares at €20-€27 per share, or about $27.77 to $37.50 per share.
Baxter International's medical products division gets a major boost in the company's 1st quarter, pushing adjusted per-share earnings 9¢ above expectations.
Illinois healthcare titan Baxter (NYSE:BAX) isn't getting much Wall Street love today after posting Q1 adjusted per-share earnings that blew away expectations.
Sales and profits were down during the 1st quarter for GE Healthcare, which cited "market volatility" for the declines.
keys: ge healthcare, general electric, earnings
GE Healthcare (NYSE:GE) saw its sales and profits decline by single digits during the 1st quarter due to "market volatility.
Former Stryker executive Mark Foldy, who pleaded guilty last year for his part in an insider trading scheme, dodges a jail sentence.
A former Stryker (NYSE:SYK) marketing executive escaped a jail sentence yesterday, instead drawing 6 months of home confinement and 2 years of probation for passing along inside information ahead of Stryker's 2011 acquisition of Orthovita.
Vital Therapies once again lowers the bar on its initial public offering, pricing the flotation at $12 per share.
Vital Therapies priced its initial public offering at $12 per share, once again lowering the bar for its 1st public flotation after scuttling its 1st try at a U.S. IPO.
Vital Therapies, which is developing a bio-artificial liver, last October set the IPO's price range at $16-$18. But the San Diego-based company but shelved the offering until March, when it set the range at $13-$15 per share.